SeaStar Medical Q2 10-Q: Going Concern Doubt, Cash Down to $7M
ICU sits 55% above its 52-week low of $2.07.
Summary
SeaStar Medical's Q2 10-Q shows revenue up 82% to $0.6M, but cash dropped to $7.0M and management raised substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · ICU
-
Going Concern Warning
Management states substantial doubt about ability to continue as a going concern; cash of $7.0M as of June 30, 2026, is insufficient to fund operations for 12 months.
-
Cash Burn Accelerates
Cash decreased $5.0M in H1 2026 to $7.0M; net cash used in operating activities was $5.8M, up from $5.7M in H1 2025.
-
Nasdaq Compliance Resolved
Mandatory Panel Monitor ended July 1, 2026; company maintained minimum stockholders' equity requirement and is no longer subject to the monitor.
-
Post-Quarter Equity Raise
Raised $0.4M via SEPA since July 1, 2026, issuing 135,339 shares; $13.8M remains available under the SEPA.
Analysis · ICU · Industrial Applications And Services
The 10-Q confirms Q2 revenue growth but reveals a critical liquidity crunch: cash fell to $7.0M from $12.0M at year-end, and management states substantial doubt about its ability to continue as a going concern for at least 12 months. The company also disclosed it raised $0.4M via its standby equity purchase agreement after quarter-end, but that is a fraction of its quarterly cash burn of roughly $2.9M. The Nasdaq compliance update is positive—the Mandatory Panel Monitor ended July 1, 2026—but the going concern warning dominates the risk profile.
At the time of this filing, ICU was trading at $3.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $2.07 to $12.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.